

Roger McIntyre

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9447373/roger-mcintyre-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

670

papers

27,981

citations

81

h-index

141

g-index

754

ext. papers

36,049

ext. citations

4.7

avg, IF

7.65

L-index

#	Paper	IF	Citations
670	A Systematic Review and Meta-Analysis of Symptoms of Anxiety, Depression, and Insomnia in Spain in the COVID-19 Crisis.. <i>International Journal of Environmental Research and Public Health</i> , 2022 , 19,	4.6	3
669	Efficacy of polysaccharide in adolescents with subthreshold depression: interim analysis of a randomized controlled study.. <i>Neural Regeneration Research</i> , 2022 , 17, 1582-1587	4.5	1
668	Immune Response to Vaccination in Adults with Mental Disorders: A Systematic Review.. <i>Journal of Affective Disorders</i> , 2022 , 304, 66-66	6.6	0
667	What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines. <i>Journal of Affective Disorders</i> , 2022 , 298, 565-576	6.6	1
666	Comparing mortality from covid-19 to mortality due to overdose: A micromort analysis. <i>Journal of Affective Disorders</i> , 2022 , 296, 514-521	6.6	3
665	Early Optimized Pharmacological Treatment in Patients With Depression and Chronic Pain.. <i>CNS Spectrums</i> , 2022 , 1-40	1.8	
664	Randomised controlled cognition trials in remitted patients with mood disorders published between 2015-2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force.. <i>Bipolar Disorders</i> , 2022 ,	3.8	2
663	The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits.. <i>Psychopharmacology</i> , 2022 , 1	4.7	1
662	Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytochemicals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.. <i>World Journal of Biological Psychiatry</i> , 2022 , 1-22	3.8	5
661	Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research.. <i>Infectious Diseases</i> , 2022 , 1-11	3.1	2
660	The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis.. <i>Expert Opinion on Drug Safety</i> , 2022 , 1-12	4.1	2
659	The effects of psychostimulants on cognitive functions in individuals with attention-deficit hyperactivity disorder: A systematic review.. <i>Journal of Psychiatric Research</i> , 2022 , 149, 252-259	5.2	0
658	Microbiome Abnormalities as a Possible Link Between Diabetes Mellitus and Mood Disorders: Pathophysiology and Implications for Treatment.. <i>Neuroscience and Biobehavioral Reviews</i> , 2022 , 104640 ⁹		0
657	Cognitive Function Mediates the Anti-suicide Effect of Repeated Intravenous Ketamine in Adult Patients With Suicidal Ideation.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 779326	5	0
656	Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review.. <i>Psychiatry Research</i> , 2022 , 312, 114579	9.9	0
655	Screening Depressive Symptoms and Incident Major Depressive Disorder Among Chinese Community Residents Using a Mobile App-Based Integrated Mental Health Care Model: Cohort Study.. <i>Journal of Medical Internet Research</i> , 2022 , 24, e30907	7.6	0
654	Social Isolation, Loneliness and Generalized Anxiety: Implications and Associations during the COVID-19 Quarantine.. <i>Brain Sciences</i> , 2021 , 11,	3.4	4

653	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.. <i>Molecular Psychiatry</i> , 2021 ,	15.1	10
652	Pharmacogenomics of ketamine: A systematic review. <i>Journal of Psychiatric Research</i> , 2021 , 145, 27-34	5.2	3
651	The Relationship Between Cognitive Dysfunction Through THINC-Integrated Tool (THINC-it) and Psychosocial Function in Chinese Patients With Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2021 , 12, 763603	5	1
650	Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence. <i>Psychiatry Research</i> , 2021 , 307, 114321	9.9	0
649	Fatigue and Cognitive Impairment in Post-COVID-19 Syndrome: A Systematic Review and Meta-Analysis.. <i>Brain, Behavior, and Immunity</i> , 2021 ,	16.6	60
648	Prevalence of Type 2 Diabetes Mellitus, Impaired Fasting Glucose, General Obesity, and Abdominal Obesity in Patients with Bipolar Disorder: A Systematic Review and Meta-analysis.. <i>Journal of Affective Disorders</i> , 2021 , 300, 449-449	6.6	3
647	The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality. <i>Journal of Psychiatric Research</i> , 2021 , 144, 312-319	5.2	1
646	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. <i>Bipolar Disorders</i> , 2021 ,	3.8	6
645	Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment. <i>CNS Spectrums</i> , 2021 , 1-26	1.8	1
644	Functional near-infrared spectroscopy during the verbal fluency task of English-Speaking adults with mood disorders: A preliminary study. <i>Journal of Clinical Neuroscience</i> , 2021 , 94, 94-101	2.2	2
643	The impact of COVID-19 pandemic on global mental health: From the general public to healthcare workers. <i>Annals of the Academy of Medicine, Singapore</i> , 2021 , 50, 198-199	2.8	5
642	A chain mediation model on COVID-19 symptoms and mental health outcomes in Americans, Asians and Europeans. <i>Scientific Reports</i> , 2021 , 11, 6481	4.9	81
641	A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions. <i>Journal of Affective Disorders</i> , 2021 , 282, 160-164	6.6	4
640	Mapping Brain Microstructure and Network Alterations in Depressive Patients with Suicide Attempts Using Generalized Q-Sampling MRI. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	1
639	Loneliness-based impaired reward system pathway: Theoretical and clinical analysis and application. <i>Psychiatry Research</i> , 2021 , 298, 113800	9.9	3
638	Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression. <i>Advances in Therapy</i> , 2021 , 38, 2795-2820	4.1	6
637	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , 2021 , 178, 383-399	11.9	67
636	Is Obesity A Determinant Of Success With Pharmacological Treatment For Depression? A Systematic Review, Meta-Analysis And Meta-Regression. <i>Journal of Affective Disorders</i> , 2021 , 287, 54-68	6.6	8

635	A Systematic review of the validity of screening depression through Facebook, Twitter, Instagram, and Snapchat. <i>Journal of Affective Disorders</i> , 2021 , 286, 360-369	6.6	9
634	Psychiatric Safety and Weight Loss Efficacy of Naltrexone/bupropion as Add-on to Antidepressant Therapy in Patients with Obesity or Overweight. <i>Journal of Affective Disorders</i> , 2021 , 289, 167-176	6.6	0
633	The relationship between childhood emotional abuse and depressive symptoms among Chinese college students: The multiple mediating effects of emotional and behavioral problems. <i>Journal of Affective Disorders</i> , 2021 , 288, 129-135	6.6	4
632	Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment. <i>Journal of Affective Disorders</i> , 2021 , 288, 210-216	6.6	1
631	Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?. <i>Journal of Sleep Research</i> , 2021 , e13400	5.8	2
630	Clinical laboratory tests and five-year incidence of major depressive disorder: a prospective cohort study of 433,890 participants from the UK Biobank. <i>Translational Psychiatry</i> , 2021 , 11, 380	8.6	0
629	The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence. <i>Psychiatry Research</i> , 2021 , 300, 113860	9.9	0
628	Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death: A Systematic Review and Meta-analysis. <i>JAMA Psychiatry</i> , 2021 , 78, 1079-1091	14.5	35
627	Inflammation and disease modification in bipolar disorders: Priority avenues for future research. <i>Bipolar Disorders</i> , 2021 , 23, 442-444	3.8	1
626	Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countries. <i>Journal of Affective Disorders</i> , 2021 , 290, 364-377	6.6	53
625	Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 104, 110032	5.5	4
624	Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Psychiatric Research</i> , 2021 , 136, 444-451	5.2	1
623	Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 105, 110126	5.5	7
622	The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Psychopharmacology</i> , 2021 , 35, 128-136	4.6	2
621	The influence of prescriber and patient gender on the prescription of benzodiazepines: evidence for stereotypes and biases?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021 , 56, 1083-1089	4.5	4
620	Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin. <i>Journal of Psychiatric Research</i> , 2021 , 133, 82-92	5.2	8
619	The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommendations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat)	4.8	15
618	The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2021 , 134, 57-68	5.2	21

617	Effects of infliximab on brain neurochemistry of adults with bipolar depression. <i>Journal of Affective Disorders</i> , 2021 , 281, 61-66	6.6	3
616	Cumulative Cardiovascular Disease Risk and Triglycerides Differentially Relate to Subdomains of Executive Function in Bipolar Disorder; preliminary findings. <i>Journal of Affective Disorders</i> , 2021 , 278, 556-562	6.6	4
615	The influence of prescriber and patient gender on the prescription of benzodiazepines: results from the Florida Medicaid Dataset. <i>CNS Spectrums</i> , 2021 , 1-5	1.8	2
614	Resting-State Functional Connectivity and Brain Network Abnormalities in Depressive Patients with Suicidal Ideation. <i>Brain Topography</i> , 2021 , 34, 234-244	4.3	4
613	Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment. <i>Psychopharmacology</i> , 2021 , 238, 917-926	4.7	6
612	The impact of COVID-19 on subthreshold depressive symptoms: a longitudinal study. <i>Epidemiology and Psychiatric Sciences</i> , 2021 , 30, e20	5.1	5
611	Development of new rapid-action treatments in mood disorders 2021 , 139-146		
610	Convolutional Neural Network-Based Deep Learning Model for Predicting Differential Suicidality in Depressive Patients Using Brain Generalized q-Sampling Imaging. <i>Journal of Clinical Psychiatry</i> , 2021 , 82,	4.6	1
609	Comparative efficacy of pharmacological treatments on measures of self-rated functional outcomes using the Sheehan Disability Scale in patients with major depressive disorder: a systematic review and network meta-analysis. <i>CNS Spectrums</i> , 2021 , 1-9	1.8	2
608	Brain-derived neurotrophic factor levels in newly diagnosed patients with bipolar disorder, their unaffected first-degree relatives and healthy controls. <i>BJPsych Open</i> , 2021 , 7, e55	5	3
607	Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2021 , 17, 575-585	3.1	11
606	Comparison of Brain Activation Patterns during Olfactory Stimuli between Recovered COVID-19 Patients and Healthy Controls: A Functional Near-Infrared Spectroscopy (fNIRS) Study. <i>Brain Sciences</i> , 2021 , 11,	3.4	17
605	Application of computerized cognitive test battery in major depressive disorder: a narrative literature review. <i>Nordic Journal of Psychiatry</i> , 2021 , 1-9	2.3	
604	Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders. <i>CNS Drugs</i> , 2021 , 35, 925-934	6.7	5
603	The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE). <i>Psychiatry Research</i> , 2021 , 302, 113993	9.9	5
602	Comparison of functional dorsal attention network alterations in breast cancer survivors before and after chemotherapy. <i>Medicine (United States)</i> , 2021 , 100, e27018	1.8	0
601	Assessment of Disrupted Brain Structural Connectome in Depressive Patients With Suicidal Ideation Using Generalized Q-Sampling MRI. <i>Frontiers in Human Neuroscience</i> , 2021 , 15, 711731	3.3	1
600	Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?. <i>Journal of Affective Disorders</i> , 2021 , 292, 714-719	6.6	4

599	Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic. <i>Psychiatry Research</i> , 2021 , 303, 114086	9.9	0
598	Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series. <i>American Journal of Geriatric Psychiatry</i> , 2021 , 29, 899-913	6.5	6
597	Suicide reduction in Canada during the COVID-19 pandemic: lessons informing national prevention strategies for suicide reduction. <i>Journal of the Royal Society of Medicine</i> , 2021 , 114, 473-479	2.3	12
596	Onset and frequency of depression in post-COVID-19 syndrome: A systematic review. <i>Journal of Psychiatric Research</i> , 2021 , 144, 129-137	5.2	25
595	Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. <i>Journal of Affective Disorders</i> , 2021 , 293, 285-294	6.6	5
594	Repetitive transcranial magnetic stimulation for cognitive function in adults with bipolar disorder: A pilot study. <i>Journal of Affective Disorders</i> , 2021 , 293, 73-77	6.6	2
593	The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. <i>Journal of Affective Disorders</i> , 2021 , 294, 592-596	6.6	1
592	Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence. <i>Journal of Psychiatric Research</i> , 2021 , 143, 209-214	5.2	0
591	Management of cognitive impairment in bipolar disorder: a systematic review of randomized controlled trials. <i>CNS Spectrums</i> , 2021 , 1-22	1.8	3
590	Economic, physical and social determinants of health during the COVID-19 lockdown: a call for renewed societal responses 2021 , 232-243		
589	The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: Bipolar disorder summary. <i>Bipolar Disorders</i> , 2020 , 22, 805-821	3.8	34
588	Call to action regarding the vascular-bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders. <i>Bipolar Disorders</i> , 2020 , 22, 440-460	3.8	34
587	The Association between Selective Serotonin Reuptake Inhibitors (SSRIs) Use and the Risk of Bladder Cancer: A Nationwide Population-Based Cohort Study. <i>Cancers</i> , 2020 , 12,	6.6	2
586	Preventing suicide in the context of the COVID-19 pandemic. <i>World Psychiatry</i> , 2020 , 19, 250-251	14.4	90
585	The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. <i>Bipolar Disorders</i> , 2020 , 22, 831-840	3.8	18
584	The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Affective Disorders</i> , 2020 , 274, 903-910	6.6	37
583	Caloric restriction, resting metabolic rate and cognitive performance in Non-obese adults: A post-hoc analysis from CALERIE study. <i>Journal of Psychiatric Research</i> , 2020 , 128, 16-22	5.2	7
582	Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1031-1040	4.1	9

581	PSYCHOMETRIC properties of the Chinese version of the THINC-it tool for cognitive symptoms in patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2020 , 273, 586-591	6.6	2
580	Effect of body anthropometrics on brain structure of offspring of parents with bipolar disorder. <i>Journal of Psychiatric Research</i> , 2020 , 124, 137-142	5.2	1
579	Modeling the Research Landscapes of Artificial Intelligence Applications in Diabetes (GAP). <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	7
578	Practical Guidelines for Managing Patients With Psoriasis on Biologics: An Update-Reader Comment. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020 , 24, 213-215	1.6	
577	The Mental Health Effects of COVID-19 on Health Care Providers in China. <i>American Journal of Psychiatry</i> , 2020 , 177, 635-636	11.9	48
576	Synergistic effect of social media use and psychological distress on depression in China during the COVID-19 epidemic. <i>Psychiatry and Clinical Neurosciences</i> , 2020 , 74, 552-554	6.2	11
575	The THINC-it Tool for Cognitive Assessment and Measurement in Major Depressive Disorder: Sensitivity to Change. <i>Frontiers in Psychiatry</i> , 2020 , 11, 546	5	8
574	Leptin mediates improvements in cognitive function following treatment with infliximab in adults with bipolar depression. <i>Psychoneuroendocrinology</i> , 2020 , 120, 104779	5	6
573	Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. <i>Brain, Behavior, and Immunity</i> , 2020 , 87, 100-106	16.6	512
572	Association of history of adverse childhood experiences with irritable bowel syndrome (IBS) in individuals with mood disorders. <i>Psychiatry Research</i> , 2020 , 288, 112967	9.9	0
571	Current and Future Vistas in Bipolar Disorder. <i>Current Behavioral Neuroscience Reports</i> , 2020 , 7, 68-75	1.7	
570	A longitudinal study on the mental health of general population during the COVID-19 epidemic in China. <i>Brain, Behavior, and Immunity</i> , 2020 , 87, 40-48	16.6	1175
569	The Association Between Adverse Childhood Experiences and Inflammation in Patients with Major Depressive Disorder: A Systematic Review. <i>Journal of Affective Disorders</i> , 2020 , 272, 1-7	6.6	10
568	Is returning to work during the COVID-19 pandemic stressful? A study on immediate mental health status and psychoneuroimmunity prevention measures of Chinese workforce. <i>Brain, Behavior, and Immunity</i> , 2020 , 87, 84-92	16.6	313
567	Association of alkali metals and Alkaline-earth metals with the risk of schizophrenia in a Chinese population: A Case-Control study. <i>Journal of Trace Elements in Medicine and Biology</i> , 2020 , 60, 126478	4.1	2
566	Development and implementation of guidelines for the management of depression: a systematic review. <i>Bulletin of the World Health Organization</i> , 2020 , 98, 683-697H	8.2	15
565	A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	4
564	Broad Efficacy of Cariprazine on Depressive Symptoms in Bipolar Disorder and the Clinical Implications. <i>primary care companion for CNS disorders, The</i> , 2020 , 22,	1.2	5

563	Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder. <i>Psychiatry Research</i> , 2020 , 284, 112767	9.9	1
562	Projected increases in suicide in Canada as a consequence of COVID-19. <i>Psychiatry Research</i> , 2020 , 290, 113104	9.9	93
561	Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence. <i>CNS Spectrums</i> , 2020 , 1-9	1.8	2
560	Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation. <i>CNS Spectrums</i> , 2020 , 1-7	1.8	1
559	Mental health conditions among the general population, healthcare workers and quarantined population during the coronavirus disease 2019 (COVID-19) pandemic. <i>Psychology, Health and Medicine</i> , 2020 , 1-13	2.1	6
558	Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a United States-based retrospective claims database analysis. <i>Journal of Medical Economics</i> , 2020 , 23, 262-270	2.4	5
557	Leptin, obesity, and response to ketamine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020 , 98, 109773	5.5	4
556	Parsing metabolic heterogeneity in mood disorders: A hypothesis-driven cluster analysis of glucose and insulin abnormalities. <i>Bipolar Disorders</i> , 2020 , 22, 79-88	3.8	7
555	A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression. <i>Journal of Affective Disorders</i> , 2020 , 263, 386-395	6.6	9
554	Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma. <i>Journal of Affective Disorders</i> , 2020 , 263, 258-266	6.6	6
553	Depression in the medically ill. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020 , 54, 346-366	2.6	13
552	The efficacy of mind-body (Baduanjin) exercise on self-reported sleep quality and quality of life in elderly subjects with sleep disturbances: a randomized controlled trial. <i>Sleep and Breathing</i> , 2020 , 24, 695-701	3.1	9
551	Acyl-Carnitine plasma levels and their association with metabolic syndrome in individuals with schizophrenia. <i>Psychiatry Research</i> , 2020 , 293, 113458	9.9	3
550	The Effect of Loneliness on Distinct Health Outcomes: A Comprehensive Review and Meta-Analysis. <i>Psychiatry Research</i> , 2020 , 294, 113514	9.9	28
549	Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: Economic burden and healthcare resource utilization. <i>Journal of Affective Disorders</i> , 2020 , 277, 30-38	6.6	9
548	Bipolar disorders. <i>Lancet, The</i> , 2020 , 396, 1841-1856	40	124
547	Impact of COVID-19 pandemic on mental health in the general population: A systematic review. <i>Journal of Affective Disorders</i> , 2020 , 277, 55-64	6.6	1546
546	The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. <i>Journal of Affective Disorders</i> , 2020 , 276, 576-584	6.6	44

545	A quantitative and qualitative study on the neuropsychiatric sequelae of acutely ill COVID-19 inpatients in isolation facilities. <i>Translational Psychiatry</i> , 2020 , 10, 355	8.6	57
544	The clinical characterization of the adult patient with depression aimed at personalization of management. <i>World Psychiatry</i> , 2020 , 19, 269-293	14.4	59
543	The Association Between Physical and Mental Health and Face Mask Use During the COVID-19 Pandemic: A Comparison of Two Countries With Different Views and Practices. <i>Frontiers in Psychiatry</i> , 2020 , 11, 569981	5	156
542	Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis. <i>CNS Spectrums</i> , 2020 , 1-9	1.8	2
541	The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: Major depression summary. <i>Bipolar Disorders</i> , 2020 , 22, 788-804	3.8	32
540	Metabolic profiling for water-soluble metabolites in patients with schizophrenia and healthy controls in a Chinese population: A case-control study. <i>World Journal of Biological Psychiatry</i> , 2020 , 21, 357-367	3.8	7
539	The effect of caloric restriction on working memory in healthy non-obese adults. <i>CNS Spectrums</i> , 2020 , 25, 2-8	1.8	22
538	Are early increases in physical activity a behavioral marker for successful antidepressant treatment?. <i>Journal of Affective Disorders</i> , 2020 , 260, 287-291	6.6	2
537	Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies. <i>CNS Spectrums</i> , 2020 , 25, 502-510	1.8	84
536	Inflammation, brain structure and cognition interrelations among individuals with differential risks for bipolar disorder. <i>Brain, Behavior, and Immunity</i> , 2020 , 83, 192-199	16.6	9
535	Effects of Lower Past-Year Serum Sodium and Hyponatremia on Depression Symptoms and Cognitive Impairments in Patients With Hemodialysis. <i>Therapeutic Apheresis and Dialysis</i> , 2020 , 24, 169-177	1.7	3
534	Registered clinical trials investigating ketamine for psychiatric disorders. <i>Journal of Psychiatric Research</i> , 2020 , 127, 1-12	5.2	14
533	What is bipolar disorder? A disease model of dysregulated energy expenditure. <i>Neuroscience and Biobehavioral Reviews</i> , 2020 , 113, 529-545	9	7
532	Mental, emotional, and behavioral effects of ketogenic diet for non-epileptic neuropsychiatric conditions. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020 , 102, 109947	5.5	6
531	Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression. <i>Cells</i> , 2020 , 9,	7.9	14
530	Impact of SARS-CoV-2 Infection on Cognitive Function: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2020 , 11, 621773	5	29
529	Metabolic profile in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. <i>International Journal of Bipolar Disorders</i> , 2019 , 7, 8	5.4	21
528	Machine learning and big data: Implications for disease modeling and therapeutic discovery in psychiatry. <i>Artificial Intelligence in Medicine</i> , 2019 , 99, 101704	7.4	39

527	Antidepressants Reduced Risk of Mortality in Patients With Diabetes Mellitus: A Population-Based Cohort Study in Taiwan. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 4619-4625	5.6	5
526	Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine. <i>Comprehensive Psychiatry</i> , 2019 , 94, 152113	7.3	23
525	Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial. <i>Journal of Psychopharmacology</i> , 2019 , 33, 1388-1394	4.6	9
524	Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression. <i>Experimental Neurology</i> , 2019 , 315, 1-8	5.7	44
523	Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study. <i>Translational Psychiatry</i> , 2019 , 9, 19	8.6	27
522	The Current Research Landscape on the Artificial Intelligence Application in the Management of Depressive Disorders: A Bibliometric Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2019 , 16,	4.6	35
521	Indices of Change, Expectations, and Popularity of Biological Treatments for Major Depressive Disorder between 1988 and 2017: A Scientometric Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2019 , 16,	4.6	20
520	Effort-based decision-making is affected by overweight/obesity in major depressive disorder. <i>Journal of Affective Disorders</i> , 2019 , 256, 221-227	6.6	8
519	Antipsychotic use is inversely associated with gastric cancer risk: A nationwide population-based nested case-control study. <i>Cancer Medicine</i> , 2019 , 8, 4484-4496	4.8	7
518	Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , 2019 , 76, 783-790	14.5	83
517	Stress, epigenetics and depression: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2019 , 102, 139-152	9	114
516	Consumer Warning for Genetic Tests Claiming to Predict Response to Medications: Implications for Psychiatry. <i>American Journal of Psychiatry</i> , 2019 , 176, 412-413	11.9	1
515	Prevalence of Burnout in Medical and Surgical Residents: A Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2019 , 16,	4.6	112
514	Early improvement in HAMD-17 and HAMD-7 scores predict response and remission in depressed patients treated with fluoxetine or electroconvulsive therapy. <i>Journal of Affective Disorders</i> , 2019 , 253, 154-161	6.6	12
513	Aberrant brain structural-functional connectivity coupling in euthymic bipolar disorder. <i>Human Brain Mapping</i> , 2019 , 40, 3452-3463	5.9	11
512	Parental characteristics and the risk of schizophrenia in a Chinese population: a case-control study. <i>Nordic Journal of Psychiatry</i> , 2019 , 73, 90-95	2.3	4
511	Advances and challenges in development of precision psychiatry through clinical metabolomics on mood and psychotic disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 93, 182-188	5.5	17
510	Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study. <i>American Journal of Psychiatry</i> , 2019 , 176, 439-448	11.9	53

509	The relationship between smartphone addiction and symptoms of depression, anxiety, and attention-deficit/hyperactivity in South Korean adolescents. <i>Annals of General Psychiatry</i> , 2019 , 18, 1	3.4	60
508	Letter to the Editor: Clinical versus statistical significance of pharmacogenomic-guided antidepressant therapy: What's really being measured and marketed?. <i>Journal of Psychiatric Research</i> , 2019 , 114, 208-209	5.2	6
507	The neural systems of emotion regulation and abnormalities in major depressive disorder. <i>Behavioural Brain Research</i> , 2019 , 367, 181-188	3.4	30
506	The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2019 , 10, 17	5	24
505	A clinical model for identifying an inflammatory phenotype in mood disorders. <i>Journal of Psychiatric Research</i> , 2019 , 113, 148-158	5.2	10
504	The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 92, 387-404	5.5	35
503	Peripheral interleukin-6 levels and working memory in non-obese adults: A post-hoc analysis from the CALERIE study. <i>Nutrition</i> , 2019 , 58, 18-22	4.8	4
502	Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease. <i>Behavioural Brain Research</i> , 2019 , 356, 271-278	3.4	39
501	Brexpiprazole as an augmentation agent to antidepressants in treatment resistant major depressive disorder. <i>Expert Review of Neurotherapeutics</i> , 2019 , 19, 777-783	4.3	5
500	Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world study. <i>Current Medical Research and Opinion</i> , 2019 , 35, 2169-2177	2.5	2
499	Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. <i>Current Medical Research and Opinion</i> , 2019 , 35, 1993-2005	2.5	28
498	Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials. <i>Journal of Affective Disorders</i> , 2019 , 257, 600-606	6.6	14
497	Association between diabetes and mood disorders and the potential use of anti-hyperglycemic agents as antidepressants. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 95, 109720	5.5	21
496	Keeping up with the clinical advances: depression. <i>CNS Spectrums</i> , 2019 , 24, 25-37	1.8	13
495	Machine learning and big data analytics in bipolar disorder: A position paper from the International Society for Bipolar Disorders Big Data Task Force. <i>Bipolar Disorders</i> , 2019 , 21, 582-594	3.8	52
494	Affective cognition in bipolar disorder: A systematic review by the ISBD targeting cognition task force. <i>Bipolar Disorders</i> , 2019 , 21, 686-719	3.8	36
493	Risk of Dementia Among Individuals With Psoriasis: A Nationwide Population-Based Cohort Study in Taiwan. <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	14
492	Oral Ketamine for Depression: A Systematic Review. <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	45

491	Differential Diagnosis of Major Depressive Disorder Versus Bipolar Disorder: Current Status and Best Clinical Practices. <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	4
490	Activating and Sedating Properties of Medications Used for the Treatment of Major Depressive Disorder and Their Effect on Patient Functioning. <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	2
489	Cariprazine for the treatment of bipolar depression: a review. <i>Expert Review of Neurotherapeutics</i> , 2019 , 19, 317-323	4.3	11
488	Global Lifetime and 12-Month Prevalence of Suicidal Behavior, Deliberate Self-Harm and Non-Suicidal Self-Injury in Children and Adolescents between 1989 and 2018: A Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2019 , 16,	4.6	81
487	Serum metabolic profiling using small molecular water-soluble metabolites in individuals with schizophrenia: A longitudinal study using a pre-post-treatment design. <i>Psychiatry and Clinical Neurosciences</i> , 2019 , 73, 100-108	6.2	13
486	Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 92, 1-7	5.5	15
485	Hypersomnia and Bipolar Disorder: A systematic review and meta-analysis of proportion. <i>Journal of Affective Disorders</i> , 2019 , 246, 659-666	6.6	15
484	The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. <i>Journal of Affective Disorders</i> , 2019 , 246, 217-223	6.6	5
483	The long-term effect of bariatric surgery on depression and anxiety. <i>Journal of Affective Disorders</i> , 2019 , 246, 886-894	6.6	51
482	Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 113-119	5.9	15
481	The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders. <i>European Neuropsychopharmacology</i> , 2019 , 29, 137-146	1.2	15
480	New use for old drugs: The protective effect of atypical antipsychotics on hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2019 , 144, 2428-2439	7.5	6
479	Cognitive impairment in major depressive disorder. <i>CNS Spectrums</i> , 2019 , 24, 22-29	1.8	40
478	Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings. <i>Journal of Affective Disorders</i> , 2019 , 245, 508-516	6.6	6
477	Expert Consensus on Screening and Assessment of Cognition in Psychiatry. <i>CNS Spectrums</i> , 2019 , 24, 154-162	1.8	9
476	A pilot case-control study on the association between N-acetyl derivatives in serum and first-episode schizophrenia. <i>Psychiatry Research</i> , 2019 , 272, 36-41	9.9	4
475	Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 92, 109-117	5.5	44
474	Possible association between social cognition and metabolic dysfunctions in Bipolar Disorder and Schizophrenia: Preliminary results. <i>Journal of Affective Disorders</i> , 2019 , 246, 828-835	6.6	7

473	Neurocognitive and neuroimaging correlates of obesity and components of metabolic syndrome in bipolar disorder: a systematic review. <i>Psychological Medicine</i> , 2019 , 49, 738-749	6.9	23
472	Thirty-year cardiovascular risk score in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019 , 53, 651-662	2.6	21
471	Comparison of serum essential trace metals between patients with schizophrenia and healthy controls. <i>Journal of Trace Elements in Medicine and Biology</i> , 2019 , 51, 79-85	4.1	22
470	Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. <i>Journal of Affective Disorders</i> , 2019 , 243, 116-120	6.6	32
469	Oligopeptidases activity in bipolar disorder: Ndel1 and angiotensin I converting enzyme. <i>Journal of Affective Disorders</i> , 2019 , 244, 67-70	6.6	5
468	Efficacy of vortioxetine in working patients with generalized anxiety disorder. <i>CNS Spectrums</i> , 2019 , 24, 249-257	1.8	4
467	Antidepressant Prescription and Risk of Lung Cancer: A Nationwide Case-Control Study. <i>Pharmacopsychiatry</i> , 2019 , 52, 134-141	2	
466	Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies. <i>Neuropsychiatric Disease and Treatment</i> , 2019 , 15, 37-45	3.1	14
465	The relationship of depression with the level of blood pressure in population-based Kangbuk Samsung Health Study. <i>Journal of the American Society of Hypertension</i> , 2018 , 12, 356-363		3
464	Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?. <i>Neuropharmacology</i> , 2018 , 136, 335-342	5.5	15
463	The impact of body mass index in gene expression of reelin pathway mediators in individuals with schizophrenia and mood disorders: A post-mortem study. <i>Journal of Psychiatric Research</i> , 2018 , 102, 186-191	5.3	4
462	Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 475-482	5.5	10
461	The relationship between inflammatory state and quantity of affective episodes in bipolar disorder. <i>Psychoneuroendocrinology</i> , 2018 , 90, 61-67	5	17
460	Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians. <i>Bipolar Disorders</i> , 2018 , 20, 184-194	3.8	87
459	The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series. <i>Perspectives in Psychiatric Care</i> , 2018 , 54, 507-513	2.2	6
458	Increased Incidence of Obstructive Sleep Apnea in Hospitalized Children After Enterovirus Infection: A Nationwide Population-based Cohort Study. <i>Pediatric Infectious Disease Journal</i> , 2018 , 37, 872-879	3.4	2
457	Effectiveness of a Type 2 Diabetes Screening Intervention in the Canadian Workplace. <i>Canadian Journal of Diabetes</i> , 2018 , 42, 493-499.e1	2.1	3
456	Targeting cytokines in reduction of depressive symptoms: A comprehensive review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018 , 83, 86-91	5.5	42

455	Association between enterovirus infection and speech and language impairments: A nationwide population-based study. <i>Research in Developmental Disabilities</i> , 2018 , 77, 76-86	2.7	4
454	Are Antidepressants Harmful in the "General Population"?. <i>Psychotherapy and Psychosomatics</i> , 2018 , 87, 179	9.4	1
453	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disorders</i> , 2018 , 20, 97-170	3.8	639
452	Depressive disorders: Processes leading to neurogeneration and potential novel treatments. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018 , 80, 189-204	5.5	29
451	A computational algorithm for personalized medicine in schizophrenia. <i>Schizophrenia Research</i> , 2018 , 192, 131-136	3.6	13
450	SSRIs associated with decreased risk of hepatocellular carcinoma: A population-based case-control study. <i>Psycho-Oncology</i> , 2018 , 27, 187-192	3.9	21
449	The differential association between history of childhood sexual abuse and body mass index in early and late stages of bipolar disorder. <i>Journal of Affective Disorders</i> , 2018 , 227, 214-218	6.6	16
448	Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 128-144	5.8	43
447	Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials. <i>Journal of Affective Disorders</i> , 2018 , 227, 219-225	6.6	92
446	Drug-drug interactions as a result of co-administering Δ^9 THC and CBD with other psychotropic agents. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 51-54	4.1	49
445	Cognitive Impairment Mediates Workplace Impairment in Adults With Type 2 Diabetes Mellitus: Results From the Motivaction Study. <i>Canadian Journal of Diabetes</i> , 2018 , 42, 289-295	2.1	12
444	Sex differences in the mediators of functional disability in Major Depressive Disorder. <i>Journal of Psychiatric Research</i> , 2018 , 96, 108-114	5.2	11
443	Food addiction: Prevalence, psychopathological correlates and associations with quality of life in a large sample. <i>Journal of Psychiatric Research</i> , 2018 , 96, 145-152	5.2	88
442	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 330-348	3.8	20
441	Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials. <i>Journal of Affective Disorders</i> , 2018 , 226, 294-300	6.6	5
440	Obesity and frontal-striatal brain structures in offspring of individuals with bipolar disorder: Results from the global mood and brain science initiative. <i>Bipolar Disorders</i> , 2018 , 20, 42-48	3.8	11
439	Risks of road injuries in patients with bipolar disorder and associations with drug treatments: A population-based matched cohort study. <i>Journal of Affective Disorders</i> , 2018 , 226, 124-131	6.6	2
438	Dosage of methylphenidate and traumatic brain injury in ADHD: a population-based study in Taiwan. <i>European Child and Adolescent Psychiatry</i> , 2018 , 27, 279-288	5.5	13

437	Gluten related illnesses and severe mental disorders: a comprehensive review. <i>Neuroscience and Biobehavioral Reviews</i> , 2018 , 84, 368-375	9	15
436	Correlation between brain circuit segregation and obesity. <i>Behavioural Brain Research</i> , 2018 , 337, 218-227	3.4	18
435	Sleep Duration and Quality as Related to Left Ventricular Structure and Function. <i>Psychosomatic Medicine</i> , 2018 , 80, 78-86	3.7	6
434	Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats. <i>Brain Research Bulletin</i> , 2018 , 142, 1-7	3.9	52
433	Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. <i>Neuroscience and Biobehavioral Reviews</i> , 2018 , 94, 11-16	9	53
432	Predicting antidepressant response using early changes in cognition: A systematic review. <i>Behavioural Brain Research</i> , 2018 , 353, 154-160	3.4	16
431	Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. <i>International Journal of Environmental Research and Public Health</i> , 2018 , 15,	4.6	47
430	Effects of Antipsychotic Drugs on the Epigenetic Modification of Brain-Derived Neurotrophic Factor Gene Expression in the Hippocampi of Chronic Restraint Stress Rats. <i>Neural Plasticity</i> , 2018 , 2018, 2682037	3.3	10
429	Probiotics for the treatment of depressive symptoms: An anti-inflammatory mechanism?. <i>Brain, Behavior, and Immunity</i> , 2018 , 73, 115-124	16.6	53
428	Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review. <i>Journal of Affective Disorders</i> , 2018 , 241, 519-532	6.6	95
427	IL-1, IL-6, TNF- α and CRP in Elderly Patients with Depression or Alzheimer's disease: Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2018 , 8, 12050	4.9	191
426	Post hoc analyses of aripiprazole treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight. <i>Neuropsychiatric Disease and Treatment</i> , 2018 , 14, 1941-1952	3.1	4
425	Effects of olanzapine and haloperidol on mTORC1 signaling, dendritic outgrowth, and synaptic proteins in rat primary hippocampal neurons under toxic conditions. <i>Neuroscience Letters</i> , 2018 , 686, 59-66	3.3	3
424	The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis. <i>Journal of Affective Disorders</i> , 2018 , 241, 484-491	6.6	59
423	Stability, reliability, and validity of the THINC-it screening tool for cognitive impairment in depression: A psychometric exploration in healthy volunteers. <i>International Journal of Methods in Psychiatric Research</i> , 2018 , 27, e1736	4.3	14
422	Differentiating Medicated Patients Suffering from Major Depressive Disorder from Healthy Controls by Spot Urine Measurement of Monoamines and Steroid Hormones. <i>International Journal of Environmental Research and Public Health</i> , 2018 , 15,	4.6	15
421	The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression. <i>International Journal of Environmental Research and Public Health</i> , 2018 , 15,	4.6	47
420	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder. <i>Journal of Affective Disorders</i> , 2018 , 238, 228-232	6.6	6

419	Leptin and adiponectin levels in major depressive disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2018 , 238, 101-110	6.6	38
418	Cardiovascular hazards of insufficient treatment of depression among patients with known cardiovascular disease: a propensity score adjusted analysis. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2018 , 4, 258-266	4.6	5
417	Gaming-addicted teens identify more with their cyber-self than their own self: Neural evidence. <i>Psychiatry Research - Neuroimaging</i> , 2018 , 279, 51-59	2.9	12
416	Therapeutic potential of JAK/STAT pathway modulation in mood disorders. <i>Reviews in the Neurosciences</i> , 2018 , 30, 1-7	4.7	19
415	Rethinking the spectrum of mood disorders: implications for diagnosis and management - Proceedings of a symposium presented at the 30th Annual European College of Neuropsychopharmacology Congress, 4 September 2017, Paris, France. <i>Therapeutic Advances in Psychopharmacology</i> , 2018 , 8, 1-16	4.9	5
414	Coronary calcium score as an expression of multisystemic progression of bipolar disorder. <i>Revista Brasileira De Psiquiatria</i> , 2018 , 40, 459-460	2.6	1
413	Arabic Translation, Validation and Cultural Adaptation of the 7-Item Hamilton Depression Rating Scale in Two Community Samples. <i>Sultan Qaboos University Medical Journal</i> , 2018 , 18, e167-e172	0.9	3
412	Association Between Bone Mineral Density and Depressive Symptoms in a Population-Based Sample. <i>Journal of Clinical Psychiatry</i> , 2018 , 79,	4.6	6
411	Randomized Controlled Trials of Psychoeducation Modalities in the Management of Bipolar Disorder: A Systematic Review. <i>Journal of Clinical Psychiatry</i> , 2018 , 79,	4.6	15
410	Factors That Impact Treatment Decisions: Results From an Online Survey of Individuals With Bipolar and Unipolar Depression. <i>primary care companion for CNS disorders, The</i> , 2018 , 20,	1.2	6
409	Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review. <i>Journal of Affective Disorders</i> , 2018 , 227, 406-415	6.6	66
408	Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders. <i>Journal of Affective Disorders</i> , 2018 , 227, 787-794	6.6	22
407	Prostate cancer and antidepressants: A nationwide population-based nested case-control study. <i>Journal of Affective Disorders</i> , 2018 , 227, 834-839	6.6	1
406	Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study. <i>Research in Developmental Disabilities</i> , 2018 , 72, 96-105	2.7	30
405	Association Between Sleep Duration, Quality and Body Mass Index in the Korean Population. <i>Journal of Clinical Sleep Medicine</i> , 2018 , 14, 1353-1360	3.1	10
404	A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults. <i>Journal of Clinical Psychopharmacology</i> , 2018 , 38, 336-343	1.7	
403	Liraglutide Activates mTORC1 Signaling and AMPA Receptors in Rat Hippocampal Neurons Under Toxic Conditions. <i>Frontiers in Neuroscience</i> , 2018 , 12, 756	5.1	10
402	Is obesity changing the phenotype of bipolar disorder from predominately euphoric toward mixed presentations?. <i>Bipolar Disorders</i> , 2018 , 20, 685-686	3.8	4

401	Expression of dopamine signaling genes in the post-mortem brain of individuals with mental illnesses is moderated by body mass index and mediated by insulin signaling genes. <i>Journal of Psychiatric Research</i> , 2018 , 107, 128-135	5.2	10
400	Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2018 , 9, 655	5	87
399	Brain structural networks and connectomes: the brain-obesity interface and its impact on mental health. <i>Neuropsychiatric Disease and Treatment</i> , 2018 , 14, 3199-3208	3.1	11
398	Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression. <i>Therapeutic Advances in Psychopharmacology</i> , 2018 , 8, 337-348	4.9	32
397	Factors Associated with the Risk of Developing Coronary Artery Disease in Medicated Patients with Major Depressive Disorder. <i>International Journal of Environmental Research and Public Health</i> , 2018 , 15,	4.6	22
396	Letter to the editor: Inadequate evidence to support improved patient outcomes with combinatorial pharmacogenomics. <i>Journal of Psychiatric Research</i> , 2018 , 107, 136-137	5.2	1
395	Revising , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018 , 52, 1173-1182	2.6	12
394	Prevalence of Depression among Migrants: A Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2018 , 15,	4.6	40
393	Agomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. <i>Life Sciences</i> , 2018 , 210, 177-184	6.8	32
392	Characterizing, Assessing, and Treating Cognitive Dysfunction in Major Depressive Disorder. <i>Harvard Review of Psychiatry</i> , 2018 , 26, 241-249	4.1	10
391	Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis. <i>Neuroscience Letters</i> , 2018 , 686, 10-16	3.3	41
390	Antidepressant medication use and nasopharyngeal cancer risk: a nationwide population-based study. <i>Neuropsychiatric Disease and Treatment</i> , 2018 , 14, 1101-1106	3.1	2
389	The effect of paroxetine, venlafaxine and bupropion administration alone and combined on spatial and aversive memory performance in rats. <i>Pharmacological Reports</i> , 2018 , 70, 1173-1179	3.9	1
388	Characterizing amino-acid biosignatures amongst individuals with schizophrenia: a case-control study. <i>Amino Acids</i> , 2018 , 50, 1013-1023	3.5	26
387	Evidence supporting a mechanistic role of sirtuins in mood and metabolic disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018 , 86, 95-101	5.5	24
386	Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2467-2471	6.7	50
385	Mental Disorders, Antidepressants, and Type 2 Diabetes. <i>JAMA Pediatrics</i> , 2018 , 172, 703-704	8.3	2
384	Inflammation and Depression in Patients With Autoimmune Disease, Diabetes, and Obesity 2018 , 377-392		1

383	Inflammation in Bipolar Disorder 2018 , 445-454		3
382	Is binge eating a cognitive disorder? Results from the International Mood Disorders Collaborative Project. <i>Annals of Clinical Psychiatry</i> , 2018 , 30, 25-31	1.4	4
381	Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. <i>Annals of Clinical Psychiatry</i> , 2018 , 30, 38-50	1.4	23
380	Frequency of use and perceived helpfulness of wellness strategies for bipolar and unipolar depression. <i>Annals of Clinical Psychiatry</i> , 2018 , 30, 296-304	1.4	6
379	Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 410-423	3.8	24
378	Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it). <i>Scandinavian Journal of Pain</i> , 2017 , 15, 62-67	1.9	8
377	Evidence for Neurocognitive Improvement After Bariatric Surgery: A Systematic Review. <i>Psychosomatics</i> , 2017 , 58, 217-227	2.6	31
376	Guidelines for the recognition and management of mixed depression. <i>CNS Spectrums</i> , 2017 , 22, 203-219	1.8	72
375	Pharmacotherapy effectiveness for clinical subgroups among children and adolescents with early onset schizophrenia. <i>Human Psychopharmacology</i> , 2017 , 32, e2585	2.3	0
374	Adverse effects of obesity on cognitive functions in individuals at ultra high risk for bipolar disorder: Results from the global mood and brain science initiative. <i>Bipolar Disorders</i> , 2017 , 19, 128-134	3.8	25
373	Cannabidiol in medical marijuana: Research vistas and potential opportunities. <i>Pharmacological Research</i> , 2017 , 121, 213-218	10.2	73
372	Microbiota abnormalities and the therapeutic potential of probiotics in the treatment of mood disorders. <i>Reviews in the Neurosciences</i> , 2017 , 28, 739-749	4.7	24
371	Plasma copeptin and metabolic dysfunction in individuals with bipolar disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2017 , 71, 624-636	6.2	6
370	Tryptophan breakdown and cognition in bipolar disorder. <i>Psychoneuroendocrinology</i> , 2017 , 81, 144-150	5	32
369	The neurogenic compound, NSI-189 phosphate: a novel multi-domain treatment capable of pro-cognitive and antidepressant effects. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 767-770	5.9	11
368	Bipolar disorder and the risk of fracture: A nationwide population-based cohort study. <i>Journal of Affective Disorders</i> , 2017 , 218, 246-252	6.6	14
367	Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study. <i>International Clinical Psychopharmacology</i> , 2017 , 32, 72-79	2.2	8
366	The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Psychopharmacology</i> , 2017 , 37, 412-418	1.7	42

365	A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. <i>Bipolar Disorders</i> , 2017 , 19, 198-213	3.8	34
364	Diagnostic clusters associated with an early onset schizophrenia diagnosis among children and adolescents. <i>Human Psychopharmacology</i> , 2017 , 32, e2589	2.3	7
363	A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder. <i>Journal of Affective Disorders</i> , 2017 , 210, 57-65	6.6	33
362	Major depressive disorder with subthreshold hypomanic (mixed) features: A real-world assessment of treatment patterns and economic burden. <i>Journal of Affective Disorders</i> , 2017 , 210, 332-337	6.6	15
361	Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. <i>CNS Spectrums</i> , 2017 , 22, 333-341	1.8	19
360	Treatment of mixed features in bipolar disorder. <i>CNS Spectrums</i> , 2017 , 22, 141-146	1.8	10
359	Sirukumab: A Potential Treatment for Mood Disorders?. <i>Advances in Therapy</i> , 2017 , 34, 78-90	4.1	23
358	Medical comorbidity in bipolar disorder: The link with metabolic-inflammatory systems. <i>Journal of Affective Disorders</i> , 2017 , 211, 99-106	6.6	55
357	BDNF and BMI effects on brain structures of bipolar offspring: results from the global mood and brain science initiative. <i>Acta Psychiatrica Scandinavica</i> , 2017 , 136, 607-614	6.5	14
356	Digital revolution in depression: A technologies update for clinicians. <i>Personalized Medicine in Psychiatry</i> , 2017 , 4-6, 1-6	1.1	8
355	The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. <i>Neuropsychiatric Disease and Treatment</i> , 2017 , 13, 2913-2919	3.1	13
354	Effects of selective serotonin reuptake inhibitors on glaucoma: A nationwide population-based study. <i>PLoS ONE</i> , 2017 , 12, e0173005	3.7	9
353	The association between methylphenidate treatment and the risk for fracture among young ADHD patients: A nationwide population-based study in Taiwan. <i>PLoS ONE</i> , 2017 , 12, e0173762	3.7	22
352	Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials. <i>International Journal of Bipolar Disorders</i> , 2017 , 5, 36	5.4	13
351	Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2017 , 15, 391-401	3.4	1
350	Air pollution, aeroallergens and suicidality: a review of the effects of air pollution and aeroallergens on suicidal behavior and an exploration of possible mechanisms. <i>Reviews on Environmental Health</i> , 2017 , 32, 343-359	3.8	10
349	Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force. <i>Bipolar Disorders</i> , 2017 , 19, 614-626	3.8	103
348	Mixed features and mixed states in psychiatry: from calculus to geometry. <i>CNS Spectrums</i> , 2017 , 22, 116-127	1.8	8

347	Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. <i>European Neuropsychopharmacology</i> , 2017 , 27, 1153-1162	1.2	28
346	Reply to Comments by Drs Glue and Menkes. <i>Journal of Clinical Psychopharmacology</i> , 2017 , 37, 384-385	1.7	
345	Efficacy of levomilnacipran extended release in treating major depressive disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 2017-2024	4	5
344	U-shaped relationship between depression and body mass index in the Korean adults. <i>European Psychiatry</i> , 2017 , 45, 72-80	6	21
343	Sudden unexpected death in bipolar disorder. <i>Journal of Affective Disorders</i> , 2017 , 223, 8-9	6.6	1
342	Factors affecting lumbar surgery outcome: A nation-wide, population-based retrospective study. <i>Journal of Affective Disorders</i> , 2017 , 222, 98-102	6.6	2
341	Online distribution channel increases article usage on Mendeley: a randomized controlled trial. <i>Scientometrics</i> , 2017 , 112, 1537-1556	3	11
340	Effects of escitalopram and paroxetine on mTORC1 signaling in the rat hippocampus under chronic restraint stress. <i>BMC Neuroscience</i> , 2017 , 18, 39	3.2	15
339	The Bipolar Illness Onset study: research protocol for the BIO cohort study. <i>BMJ Open</i> , 2017 , 7, e0154623		81
338	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. <i>Journal of Affective Disorders</i> , 2017 , 222, 14-20	6.6	20
337	Selfish brain and selfish immune system interplay: A theoretical framework for metabolic comorbidities of mood disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2017 , 72, 43-49	9	21
336	The association between insulin resistance and depression in the Korean general population. <i>Journal of Affective Disorders</i> , 2017 , 208, 553-559	6.6	24
335	The interface of depression and obesity. <i>Obesity Research and Clinical Practice</i> , 2017 , 11, 1-10	5.4	136
334	Personalized medicine in psychiatry. <i>Nordic Journal of Psychiatry</i> , 2017 , 71, 12-19	2.3	37
333	Antidepressants and colorectal cancer: A population-based nested case-control study. <i>Journal of Affective Disorders</i> , 2017 , 207, 353-358	6.6	12
332	Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. <i>Journal of Affective Disorders</i> , 2017 , 207, 114-120	6.6	75
331	Treatment recommendations for DSM-5-defined mixed features. <i>CNS Spectrums</i> , 2017 , 22, 147-154	1.8	12
330	Gut Microbiota, Bacterial Translocation, and Interactions with Diet: Pathophysiological Links between Major Depressive Disorder and Non-Communicable Medical Comorbidities. <i>Psychotherapy and Psychosomatics</i> , 2017 , 86, 31-46	9.4	125

329	A review of the neurobiology of obesity and the available pharmacotherapies. <i>CNS Spectrums</i> , 2017 , 22, 29-38	1.8	11
328	Cognitive Impairment in Patients With Depression: Awareness, Assessment, and Management. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 1383-1394	4.6	53
327	Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications. <i>Brain Sciences</i> , 2017 , 7,	3.4	102
326	Asthma, corticosteroid use and schizophrenia: A nationwide population-based study in Taiwan. <i>PLoS ONE</i> , 2017 , 12, e0173063	3.7	14
325	Chronic administration of fluoxetine and pro-inflammatory cytokine change in a rat model of depression. <i>PLoS ONE</i> , 2017 , 12, e0186700	3.7	101
324	Hepatocellular carcinoma and antidepressants: a nationwide population-based study. <i>Oncotarget</i> , 2017 , 8, 30464-30470	3.3	17
323	Role of Proinflammatory Cytokines in Dopaminergic System Disturbances, Implications for Anhedonic Features of MDD. <i>Current Pharmaceutical Design</i> , 2017 , 23, 2065-2072	3.3	19
322	Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 720-729	4.6	92
321	Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 703-713	4.6	34
320	Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 115-121	4.6	55
319	The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction: Validation in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 873-881	4.6	63
318	Assessment of brain functional connectome alternations and correlation with depression and anxiety in major depressive disorders. <i>PeerJ</i> , 2017 , 5, e3147	3.1	16
317	Available Tools for Assessing Cognitive Impairment in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, e1427	4.6	
316	Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017 , 16, 891-899	2.6	15
315	Implementing treatment strategies for different types of depression. <i>Journal of Clinical Psychiatry</i> , 2016 , 77 Suppl 1, 9-15	4.6	4
314	Selection of cognitive tests for trials of therapeutic agents. <i>Lancet Psychiatry</i> , 2016 , 3, 499	23.3	13
313	Endometrial cancer and antidepressants: A nationwide population-based study. <i>Medicine (United States)</i> , 2016 , 95, e4178	1.8	8
312	Association of treatment response with obesity and other metabolic risk factors in adults with depressive disorders: Results from a National Depression Cohort study in Korea (the CRESCEND study). <i>Journal of Affective Disorders</i> , 2016 , 203, 190-198	6.6	15

311	Association of serum interleukin-6 with mental health problems in children exposed to perinatal complications and social disadvantage. <i>Psychoneuroendocrinology</i> , 2016 , 71, 94-101	5	6
310	Bipolar disorder course, impaired glucose metabolism and antioxidant enzymes activities: A preliminary report. <i>Journal of Psychiatric Research</i> , 2016 , 80, 38-44	5.2	12
309	Sleep and Inflammation: Implications for Domain Approach and Treatment Opportunities. <i>Biological Psychiatry</i> , 2016 , 80, 9-11	7.9	7
308	The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. <i>International Journal of Neuropsychopharmacology</i> , 2016 , 19,	5.8	104
307	A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect. <i>Journal of Clinical Psychopharmacology</i> , 2016 , 36, 50-6	1.7	46
306	Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. <i>Bipolar Disorders</i> , 2016 , 18, 89-101	3.8	125
305	Adipokines, metabolic dysfunction and illness course in bipolar disorder. <i>Journal of Psychiatric Research</i> , 2016 , 74, 63-9	5.2	38
304	Binge eating in adults with mood disorders: Results from the International Mood Disorders Collaborative Project. <i>Obesity Research and Clinical Practice</i> , 2016 , 10, 531-543	5.4	14
303	Impaired glucose metabolism moderates the course of illness in bipolar disorder. <i>Journal of Affective Disorders</i> , 2016 , 195, 57-62	6.6	19
302	Mapping inflammation onto mood: Inflammatory mediators of anhedonia. <i>Neuroscience and Biobehavioral Reviews</i> , 2016 , 64, 148-66	9	79
301	Bipolar Disorder and Inflammation. <i>Psychiatric Clinics of North America</i> , 2016 , 39, 125-37	3.1	83
300	The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project. <i>Therapeutic Advances in Chronic Disease</i> , 2016 , 7, 153-6	4.9	23
299	Shared and divergent neurocognitive impairments in adult patients with schizophrenia and bipolar disorder: Whither the evidence?. <i>Neuroscience and Biobehavioral Reviews</i> , 2016 , 61, 66-89	9	28
298	Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder. <i>Current Medical Research and Opinion</i> , 2016 , 32, 587-99	2.5	5
297	Asenapine: Efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder. <i>Journal of Affective Disorders</i> , 2016 , 190, 103-110	6.6	25
296	Abdominal obesity is associated with impaired cognitive function in euthymic bipolar individuals. <i>World Journal of Biological Psychiatry</i> , 2016 , 17, 535-46	3.8	41
295	Socioeconomic Disadvantage Moderates the Association between Peripheral Biomarkers and Childhood Psychopathology. <i>PLoS ONE</i> , 2016 , 11, e0160455	3.7	12
294	Repurposing of Anti-Diabetic Agents for the Treatment of Cognitive Impairment and Mood Disorders. <i>Current Molecular Medicine</i> , 2016 , 16, 465-73	2.5	5

293	Mood Stabilizers, Oxidative Stress and Antioxidative Defense in Euthymia of Bipolar Disorder. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016 , 15, 381-9	2.6	17
292	The Adverse Effects of Smoking on Health Outcomes in Bipolar Disorder: A Review and Synthesis of Biological Mechanisms. <i>Current Molecular Medicine</i> , 2016 , 16, 187-205	2.5	7
291	Cognitive Deficits as a Mediator of Poor Occupational Function in Remitted Major Depressive Disorder Patients. <i>Clinical Psychopharmacology and Neuroscience</i> , 2016 , 14, 1-16	3.4	86
290	Obesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature Review. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	47
289	Nitric Oxide and Major Depressive Disorder: Pathophysiology and Treatment Implications. <i>Current Molecular Medicine</i> , 2016 , 16, 206-15	2.5	44
288	Depression and Disturbed Bone Metabolism: A Narrative Review of the Epidemiological Findings and Postulated Mechanisms. <i>Current Molecular Medicine</i> , 2016 , 16, 165-78	2.5	17
287	Fibromyalgia and Bipolar Disorder: Emerging Epidemiological Associations and Shared Pathophysiology. <i>Current Molecular Medicine</i> , 2016 , 16, 119-36	2.5	19
286	Bipolar disorders, type 2 diabetes mellitus, and the brain. <i>Current Opinion in Psychiatry</i> , 2016 , 29, 1-6	4.9	19
285	Pharmacologic implications of inflammatory comorbidity in bipolar disorder. <i>Current Opinion in Pharmacology</i> , 2016 , 29, 63-9	5.1	16
284	An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2016 , 31, 134-46	2.2	13
283	Brain-derived neurotrophic factor, impaired glucose metabolism, and bipolar disorder course. <i>Bipolar Disorders</i> , 2016 , 18, 373-8	3.8	17
282	TrendMD: Helping scholarly content providers reach larger and more targeted audiences. <i>Learned Publishing</i> , 2016 , 29, 125-129	1.8	4
281	Extracellular matrix proteins matrix metalloproteinase 9 (MMP9) and soluble intercellular adhesion molecule 1 (sICAM-1) and correlations with clinical staging in euthymic bipolar disorder. <i>Bipolar Disorders</i> , 2016 , 18, 155-63	3.8	19
280	Association of Tic Disorders and Enterovirus Infection: A Nationwide Population-Based Study. <i>Medicine (United States)</i> , 2016 , 95, e3347	1.8	17
279	Cognition in major depressive disorder: a 'Systemically Important Functional Index' (SIFI). <i>Current Opinion in Psychiatry</i> , 2016 , 29, 48-55	4.9	49
278	Assessment of abnormal brain structures and networks in major depressive disorder using morphometric and connectome analyses. <i>Journal of Affective Disorders</i> , 2016 , 205, 103-111	6.6	35
277	Assessing and measuring cognitive function in major depressive disorder. <i>Evidence-Based Mental Health</i> , 2016 , 19, 106-109	11.1	18
276	The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials. <i>CNS Spectrums</i> , 2016 , 21, 385-392	1.8	7

275	Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project. <i>CNS Spectrums</i> , 2016 , 21, 362-366	1.8	18
274	The 'WikiGuidelines' smartphone application: Bridging the gaps in availability of evidence-based smartphone mental health applications. <i>Technology and Health Care</i> , 2016 , 24, 587-90	1.1	9
273	A pragmatic approach to the diagnosis and treatment of mixed features in adults with mood disorders. <i>CNS Spectrums</i> , 2016 , 21, 25-33	1.8	5
272	Physical activity preferences of individuals diagnosed with schizophrenia or bipolar disorder. <i>BMC Research Notes</i> , 2016 , 9, 340	2.3	20
271	Admixture analysis of age at onset in first episode bipolar disorder. <i>Journal of Affective Disorders</i> , 2016 , 201, 88-94	6.6	9
270	Brexipiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials. <i>Journal of Affective Disorders</i> , 2016 , 201, 116-23	6.6	23
269	Tianeptine induces mTORC1 activation in rat hippocampal neurons under toxic conditions. <i>Psychopharmacology</i> , 2016 , 233, 2617-27	4.7	5
268	Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies. <i>Journal of Affective Disorders</i> , 2016 , 206, 151-160	6.6	12
267	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. <i>Canadian Journal of Psychiatry</i> , 2016 , 61, 540-60	4.8	469
266	Inter-relation between brain-derived neurotrophic factor and antioxidant enzymes in bipolar disorder. <i>Bipolar Disorders</i> , 2016 , 18, 433-9	3.8	9
265	The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>International Journal of Neuropsychopharmacology</i> , 2015 , 19,	5.8	121
264	Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis. <i>Psychoneuroendocrinology</i> , 2015 , 62, 18-26	5	59
263	Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 1291-304	4.1	36
262	Causes of decreased life expectancy over the life span in bipolar disorder. <i>Journal of Affective Disorders</i> , 2015 , 180, 142-7	6.6	105
261	Body fat distribution and associations with metabolic and clinical characteristics in bipolar individuals. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015 , 265, 313-9	5.1	17
260	Real-world determinants of adjunctive antipsychotic prescribing for patients with major depressive disorder and inadequate response to antidepressants: a case review study. <i>Advances in Therapy</i> , 2015 , 32, 429-44	4.1	17
259	The non-glycemic effects of incretin therapies on cardiovascular outcomes, cognitive function and bone health. <i>Expert Review of Endocrinology and Metabolism</i> , 2015 , 10, 101-114	4.1	3
258	Are medical comorbid conditions of bipolar disorder due to immune dysfunction?. <i>Acta Psychiatrica Scandinavica</i> , 2015 , 132, 180-91	6.5	62

257	Correlates of benzodiazepine use in major depressive disorder: The effect of anhedonia. <i>Journal of Affective Disorders</i> , 2015 , 187, 101-5	6.6	14
256	Prevalence of fibromyalgia and co-morbid bipolar disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2015 , 188, 134-42	6.6	16
255	Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: Evidence, pathophysiology and treatment implications. <i>Journal of Affective Disorders</i> , 2015 , 188, 149-59	6.6	94
254	Evidence to support peripheral and central IL-6 signaling targets to treat depression. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 991-2	5.9	1
253	Major Depressive Disorder and Bipolar Disorder Predispose Youth to Accelerated Atherosclerosis and Early Cardiovascular Disease: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2015 , 132, 965-86	16.7	264
252	P2.f.018 Effect of adjunctive brexpiprazole (OPC-34712) on depressive symptoms in patients with symptoms of anxious distress: results from post-hoc analyses. <i>European Neuropsychopharmacology</i> , 2015 , 25, S444-S445	1.2	1
251	The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. <i>Comprehensive Psychiatry</i> , 2015 , 56, 279-82	7.3	94
250	Sex hormone binding globulin and verbal memory in older men. <i>American Journal of Geriatric Psychiatry</i> , 2015 , 23, 253-60	6.5	13
249	Peripheral markers of oxidative stress and antioxidative defense in euthymia of bipolar disorder--Gender and obesity effects. <i>Journal of Affective Disorders</i> , 2015 , 172, 367-74	6.6	39
248	Screening for bipolar spectrum disorders: A comprehensive meta-analysis of accuracy studies. <i>Journal of Affective Disorders</i> , 2015 , 172, 337-46	6.6	51
247	The prevalence and illness characteristics of DSM-5-defined "mixed feature specifier" in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project. <i>Journal of Affective Disorders</i> , 2015 , 172, 259-64	6.6	71
246	Weight cycling in bipolar disorder. <i>Journal of Affective Disorders</i> , 2015 , 171, 33-8	6.6	26
245	Risk factors for incident major depressive disorder in children and adolescents with attention-deficit/hyperactivity disorder. <i>European Child and Adolescent Psychiatry</i> , 2015 , 24, 65-73	5.5	23
244	Treating to target in major depressive disorder: response to remission to functional recovery. <i>CNS Spectrums</i> , 2015 , 20 Suppl 1, 20-30; quiz 31	1.8	24
243	Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2015 , 35, 706-10	1.7	9
242	Invasive Cervical Cancer and Antidepressants: A Nationwide Population-Based Study. <i>Medicine (United States)</i> , 2015 , 94, e1866	1.8	7
241	Depression and employment status in primary and tertiary care settings. <i>Canadian Journal of Psychiatry</i> , 2015 , 60, 14-22	4.8	43
240	The Involvement of TNF- α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments. <i>Current Neuropharmacology</i> , 2015 , 13, 558-76	7.6	80

239	Autonomic Dysfunction and Depression: A Biomarker of MDD Across the Life Span. <i>Current Psychiatry Reviews</i> , 2015 , 11, 1-7	0.9	4
238	Antidepressants and Gastric Cancer: A Nationwide Population-Based Nested Case-Control Study. <i>PLoS ONE</i> , 2015 , 10, e0143668	3.7	17
237	Religious coping and its influence on psychological distress, medication adherence, and quality of life in inflammatory bowel disease. <i>Revista Brasileira De Psiquiatria</i> , 2015 , 37, 219-27	2.6	30
236	Autobiographical Memory Disturbances in Depression: A Novel Therapeutic Target?. <i>Neural Plasticity</i> , 2015 , 2015, 759139	3.3	40
235	Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review. <i>Current Neuropharmacology</i> , 2015 , 13, 636-55	7.6	40
234	The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. <i>CNS Drugs</i> , 2015 , 29, 577-89	6.7	77
233	Is there a "metabolic-mood syndrome"? A review of the relationship between obesity and mood disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2015 , 52, 89-104	9	185
232	Novel investigational drugs targeting IL-6 signaling for the treatment of depression. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 459-75	5.9	35
231	Cerebral White Matter Lesions and Affective Episodes Correlate in Male Individuals with Bipolar Disorder. <i>PLoS ONE</i> , 2015 , 10, e0135313	3.7	12
230	From Randomized Controlled Trials of Antidepressant Drugs to the Meta-Analytic Synthesis of Evidence: Methodological Aspects Lead to Discrepant Findings. <i>Current Neuropharmacology</i> , 2015 , 13, 605-15	7.6	8
229	Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. <i>Journal of Clinical Psychiatry</i> , 2015 , 76, 398-405	4.6	49
228	Cognitive dysfunction in depression - pathophysiology and novel targets. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 1819-35	2.6	66
227	Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. <i>Journal of Affective Disorders</i> , 2014 , 156, 1-7	6.6	242
226	The theory of bipolar disorder as an illness of accelerated aging: implications for clinical care and research. <i>Neuroscience and Biobehavioral Reviews</i> , 2014 , 42, 157-69	9	105
225	Predominant polarity as a course specifier for bipolar disorder: a systematic review. <i>Journal of Affective Disorders</i> , 2014 , 163, 56-64	6.6	58
224	Targeting the inflammatory pathway as a therapeutic tool for major depression. <i>NeuroImmunoModulation</i> , 2014 , 21, 131-9	2.5	34
223	The mechanism, efficacy, and tolerability profile of agomelatine. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 259-74	4	15
222	Inflamed moods: a review of the interactions between inflammation and mood disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014 , 53, 23-34	5.5	363

221	Implications of epigenetic modulation for novel treatment approaches in patients with schizophrenia. <i>Neuropharmacology</i> , 2014 , 77, 481-6	5.5	12
220	Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5. <i>Journal of Affective Disorders</i> , 2014 , 168, 136-41	6.6	22
219	Adipokines as emerging depression biomarkers: a systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2014 , 59, 28-37	5.2	72
218	The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial. <i>Psychiatry Research</i> , 2014 , 220, 245-50	9.9	37
217	A vision for drug discovery and development: novel targets and multilateral partnerships. <i>Advances in Therapy</i> , 2014 , 31, 245-6	4.1	20
216	Early switching strategies in antidepressant non-responders: current evidence and future research directions. <i>CNS Drugs</i> , 2014 , 28, 601-9	6.7	46
215	Diabetes mellitus and disturbances in brain connectivity: a bidirectional relationship?. <i>NeuroMolecular Medicine</i> , 2014 , 16, 658-68	4.6	23
214	Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. <i>Journal of Affective Disorders</i> , 2014 , 164, 57-62	6.6	31
213	Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2014 , 161, 123-6	6.6	33
212	Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials. <i>Cancer Treatment Reviews</i> , 2014 , 40, 349-55	14.4	29
211	Metabolic syndrome and elevated C-reactive protein levels in elderly patients with newly diagnosed depression. <i>Psychosomatics</i> , 2014 , 55, 640-9	2.6	14
210	Psychosocial predictors of health outcomes in colorectal cancer: a comprehensive review. <i>Cancer Treatment Reviews</i> , 2014 , 40, 800-9	14.4	38
209	Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate. <i>CNS Spectrums</i> , 2014 , 19, 182-96	1.8	3
208	Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment. <i>Canadian Journal of Psychiatry</i> , 2014 , 59, 649-54	4.8	189
207	Treatment-resistant depression in primary care across Canada. <i>Canadian Journal of Psychiatry</i> , 2014 , 59, 349-57	4.8	83
206	Treatment implications of predominant polarity and the polarity index: a comprehensive review. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 18,	5.8	23
205	Desvenlafaxine for the treatment of major depressive disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1449-63	4	10
204	Depression, Diabetes and Dementia. <i>Key Issues in Mental Health</i> , 2014 , 42-53		1

203	Major depressive disorder and cognitive impairment. <i>Journal of Psychiatry and Neuroscience</i> , 2014 , 39, E36-7	4.5	4
202	Advancing biomarker research: utilizing 'Big Data' approaches for the characterization and prevention of bipolar disorder. <i>Bipolar Disorders</i> , 2014 , 16, 531-47	3.8	47
201	Sex differences in rates of obesity in bipolar disorder: postulated mechanisms. <i>Bipolar Disorders</i> , 2014 , 16, 83-92	3.8	21
200	Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report. <i>Bipolar Disorders</i> , 2014 , 16, 432-40	3.8	51
199	Increased body mass index makes an impact on brain white-matter integrity in adults with remitted first-episode mania. <i>Psychological Medicine</i> , 2014 , 44, 533-41	6.9	23
198	The integrative management of treatment-resistant depression: a comprehensive review and perspectives. <i>Psychotherapy and Psychosomatics</i> , 2014 , 83, 70-88	9.4	75
197	A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 17, 1557-67	5.8	252
196	Screening for bipolar depression in family medicine practices: prevalence and clinical correlates. <i>Journal of Affective Disorders</i> , 2014 , 162, 120-7	6.6	5
195	Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 1804-18	2.6	113
194	Towards a "metabolic" subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 1693-707	2.6	38
193	Are major depressive disorder and diabetes mellitus amyloidogenic conditions?. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 1667-76	2.6	4
192	Major depressive disorder and type II diabetes mellitus: mechanisms underlying risk for Alzheimer's disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 1740-9	2.6	10
191	The putative impact of metabolic health on default mode network activity and functional connectivity in neuropsychiatric disorders. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 1750-8	2.6	13
190	Gut emotions - mechanisms of action of probiotics as novel therapeutic targets for depression and anxiety disorders. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 1770-86	2.6	44
189	Metformin: repurposing opportunities for cognitive and mood dysfunction. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 1836-45	2.6	14
188	Rapid cycling in bipolar disorder: a systematic review. <i>Journal of Clinical Psychiatry</i> , 2014 , 75, e578-86	4.6	64
187	Correlates of incident bipolar disorder in children and adolescents diagnosed with attention-deficit/hyperactivity disorder. <i>Journal of Clinical Psychiatry</i> , 2014 , 75, e1278-83	4.6	19
186	Cognition in Major Depressive Disorder 2014 ,		3

185	Recognition of bipolar disorder type I before the first manic episode: challenges and developments. <i>Expert Review of Neurotherapeutics</i> , 2013 , 13, 795-806; quiz 807	4.3	7
184	Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. <i>Depression and Anxiety</i> , 2013 , 30, 515-27	8.4	423
183	Effects of doxycycline on depressive-like behavior in mice after lipopolysaccharide (LPS) administration. <i>Journal of Psychiatric Research</i> , 2013 , 47, 1521-9	5.2	126
182	The effect of personality dimensions on functional outcomes in mood disorders. <i>Advances in Therapy</i> , 2013 , 30, 671-83	4.1	3
181	Obesity and mental illness: implications for cognitive functioning. <i>Advances in Therapy</i> , 2013 , 30, 577-88	4.1	9
180	Sleep architecture variation: a mediator of metabolic disturbance in individuals with major depressive disorder. <i>Sleep Medicine</i> , 2013 , 14, 943-9	4.6	28
179	Selfish brain and neuroprogression in bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013 , 43, 66-71	5.5	21
178	The effect of bariatric surgery on psychiatric course among patients with bipolar disorder. <i>Bipolar Disorders</i> , 2013 , 15, 753-63	3.8	28
177	Obesity and bipolar disorder: synergistic neurotoxic effects?. <i>Advances in Therapy</i> , 2013 , 30, 987-1006	4.1	24
176	Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrenergic pathways. <i>Journal of Psychopharmacology</i> , 2013 , 27, 1032-43	4.6	81
175	The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder. <i>Expert Review of Neurotherapeutics</i> , 2013 , 13, 1161-82	4.3	4
174	Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy. <i>Expert Review of Neurotherapeutics</i> , 2013 , 13, 1183-200	4.3	6
173	The impact of obesity on quality of life. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2013 , 27, 139-46	6.5	118
172	Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation. <i>Journal of Affective Disorders</i> , 2013 , 151, 573-581	6.6	34
171	Early improvement as a predictor of acute treatment outcome in manic or mixed episodes in bipolar-1 disorder: a pooled, post hoc analysis from the asenapine development program. <i>Journal of Affective Disorders</i> , 2013 , 150, 745-52	6.6	10
170	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. <i>Bipolar Disorders</i> , 2013 , 15, 1-44	3.8	583
169	The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. <i>Bipolar Disorders</i> , 2013 , 15, 58-60	3.8	12
168	Is there a role for curcumin in the treatment of bipolar disorder?. <i>Medical Hypotheses</i> , 2013 , 80, 606-12	3.8	19

167	Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated bipolar disorder guidelines. <i>Bipolar Disorders</i> , 2013 , 15, 338-9	3.8	1
166	Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2013 , 150, 639-43	6.6	6
165	Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2013 , 37, 911-29	9	77
164	DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data. <i>Journal of Affective Disorders</i> , 2013 , 150, 378-83	6.6	53
163	The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. <i>Behavioural Brain Research</i> , 2013 , 237, 164-71	3.4	60
162	The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. <i>Human Psychopharmacology</i> , 2013 , 28, 421-7	2.3	16
161	Effects of lithium on oxidative stress and behavioral alterations induced by lisdexamfetamine dimesylate: relevance as an animal model of mania. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013 , 43, 230-7	5.5	35
160	Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. <i>Journal of Clinical Psychopharmacology</i> , 2013 , 33, 740-6	1.7	50
159	Conceptualising the neurobiology of fatigue. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013 , 47, 312-6	2.6	14
158	Fatigue and occupational functioning in major depressive disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013 , 47, 989-91	2.6	13
157	A review of FDA-approved treatment options in bipolar depression. <i>CNS Spectrums</i> , 2013 , 18 Suppl 1, 4-20; quiz 21	1.8	20
156	Cognitive enhancement in Canadian medical students. <i>Journal of Psychoactive Drugs</i> , 2013 , 45, 360-5	3.6	37
155	Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy. <i>International Journal of Neuropsychopharmacology</i> , 2013 , 16, 1755-65	5.8	4
154	A review of electroencephalographic changes in diabetes mellitus in relation to major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2013 , 9, 143-50	3.1	13
153	Seasonal and temperamental contributions in patients with bipolar disorder and metabolic syndrome. <i>Revista Brasileira De Psiquiatria</i> , 2013 , 35, 210	2.6	6
152	Using measurement strategies to identify and monitor residual symptoms. <i>Journal of Clinical Psychiatry</i> , 2013 , 74 Suppl 2, 14-8	4.6	15
151	Towards a multifactorial approach for prediction of bipolar disorder in at risk populations. <i>Journal of Affective Disorders</i> , 2012 , 140, 82-91	6.6	77
150	Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. <i>Bipolar Disorders</i> , 2012 , 14 Suppl 2, 1-21	3.8	33

149	Efficacy of antimanic treatments in mixed states. <i>Bipolar Disorders</i> , 2012 , 14 Suppl 2, 22-36	3.8	24
148	Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement. <i>Canadian Journal of Psychiatry</i> , 2012 , 57, 782-8	4.8	23
147	Beyond pharmacotherapy: understanding the links between obesity and chronic mental illness. <i>Canadian Journal of Psychiatry</i> , 2012 , 57, 5-12	4.8	47
146	A theoretical framework informing research about the role of stress in the pathophysiology of bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012 , 39, 1-8	5.5	33
145	Effects of alpha-lipoic acid in an animal model of mania induced by D-amphetamine. <i>Bipolar Disorders</i> , 2012 , 14, 707-18	3.8	42
144	Novel therapeutic targets in depression: minocycline as a candidate treatment. <i>Behavioural Brain Research</i> , 2012 , 235, 302-17	3.4	135
143	The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. <i>European Psychiatry</i> , 2012 , 27, 223-8	6	79
142	Screening for bipolar disorder in the primary care: a Brazilian survey. <i>Journal of Affective Disorders</i> , 2012 , 143, 118-24	6.6	9
141	A review of published evidence reporting on the efficacy and pharmacology of lurasidone. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1653-9	4	8
140	The neurobiology of the EEG biomarker as a predictor of treatment response in depression. <i>Neuropharmacology</i> , 2012 , 63, 507-13	5.5	118
139	Inflammatory cytokines as an underlying mechanism of the comorbidity between bipolar disorder and migraine. <i>Medical Hypotheses</i> , 2012 , 78, 601-5	3.8	21
138	A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. <i>Bipolar Disorders</i> , 2012 , 14, 697-706	3.8	64
137	Admixture analysis of age at onset in major depressive disorder. <i>General Hospital Psychiatry</i> , 2012 , 34, 686-91	5.6	15
136	Treatment-emergent adverse events associated with atypical antipsychotics. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1587-98	4	47
135	Economic grand rounds: economic costs of failure to monitor adverse effects of second-generation antipsychotics: an underestimated factor. <i>Psychiatric Services</i> , 2012 , 63, 202-4	3.3	8
134	The association between childhood adversity and components of metabolic syndrome in adults with mood disorders: results from the international mood disorders collaborative project. <i>International Journal of Psychiatry in Medicine</i> , 2012 , 43, 165-77	1	55
133	Understanding the Concept of Noise in Mental Health Care Encounters With Patients From Different Cultures. <i>Home Health Care Management and Practice</i> , 2012 , 24, 81-87	0.9	
132	Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2012 , 5, 217-20	1.6	15

131	Crosstalk between metabolic and neuropsychiatric disorders. <i>F1000 Biology Reports</i> , 2012 , 4, 14		37
130	The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. <i>Annals of Clinical Psychiatry</i> , 2012 , 24, 6-22	1.4	63
129	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. <i>Annals of Clinical Psychiatry</i> , 2012 , 24, 23-37	1.4	67
128	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. <i>Annals of Clinical Psychiatry</i> , 2012 , 24, 38-55	1.4	38
127	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid personality disorders. <i>Annals of Clinical Psychiatry</i> , 2012 , 24, 56-68	1.4	24
126	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. <i>Annals of Clinical Psychiatry</i> , 2012 , 24, 69-81	1.4	64
125	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. <i>Annals of Clinical Psychiatry</i> , 2012 , 24, 91-109	1.4	51
124	Managing medical and psychiatric comorbidity in individuals with major depressive disorder and bipolar disorder. <i>Annals of Clinical Psychiatry</i> , 2012 , 24, 163-9	1.4	50
123	Effects of once-daily adjunct quetiapine XR on sleep disturbance in patients with mdd: a pooled analysis from two acute studies. <i>European Psychiatry</i> , 2011 , 26, 608-608	6	
122	Asenapine: a review of acute and extension phase data in bipolar disorder. <i>CNS Neuroscience and Therapeutics</i> , 2011 , 17, 645-8	6.8	15
121	Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence. <i>Neuropsychiatric Disease and Treatment</i> , 2011 , 7, 319-23	3.1	13
120	Aripiprazole: striving towards euthymia with a novel mechanism of action. <i>Journal of Affective Disorders</i> , 2011 , 128 Suppl 1, S1-2	6.6	2
119	Depression in the workforce: the intermediary effect of medical comorbidity. <i>Journal of Affective Disorders</i> , 2011 , 128 Suppl 1, S29-36	6.6	38
118	Neurocognitive-genetic and neuroimaging-genetic research paradigms in schizophrenia and bipolar disorder. <i>Journal of Neural Transmission</i> , 2011 , 118, 1621-39	4.3	22
117	Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. <i>NeuroMolecular Medicine</i> , 2011 , 13, 93-116	4.6	119
116	Surgical treatment of morbid obesity among patients with bipolar disorder: a research agenda. <i>Advances in Therapy</i> , 2011 , 28, 389-400	4.1	11
115	Childhood treatment with psychotropic medication and development of comorbid medical conditions in adolescent-onset bipolar disorder. <i>Human Psychopharmacology</i> , 2011 , 26, 451-9	2.3	17
114	Insulin dysfunction and allostatic load in bipolar disorder. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 1017-28	4.3	41

113	Performance improvement CME: Long-term treatment of bipolar disorder. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, e09	4.6	7
112	Long-term treatment of bipolar disorder in adults. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, e06	4.6	6
111	Implementing guideline-based strategies to avoid relapse and recurrence in depression. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, e35	4.6	
110	Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. <i>Journal of Evaluation in Clinical Practice</i> , 2010 , 16, 744-55	2.5	21
109	Neurosurgical treatment of bipolar depression: defining treatment resistance and identifying surgical targets. <i>Bipolar Disorders</i> , 2010 , 12, 691-701	3.8	19
108	Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder. <i>Expert Review of Neurotherapeutics</i> , 2010 , 10, 645-9	4.3	13
107	Aerobic physical exercise as a possible treatment for neurocognitive dysfunction in bipolar disorder. <i>Postgraduate Medicine</i> , 2010 , 122, 107-16	3.7	40
106	Atypical antipsychotic tolerability and switching strategies in bipolar disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2827-37	4	13
105	The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. <i>CNS Drugs</i> , 2010 , 24, 741-53	6.7	57
104	P.2.a.034 Impact of methodology on the efficacy of extended release quetiapine fumarate in major depressive disorder. <i>European Neuropsychopharmacology</i> , 2010 , 20, S353	1.2	2
103	Frequency and correlates of gambling problems in outpatients with major depressive disorder and bipolar disorder. <i>Canadian Journal of Psychiatry</i> , 2010 , 55, 568-76	4.8	39
102	Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders?. <i>Advances in Therapy</i> , 2010 , 27, 63-80	4.1	57
101	The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder. <i>Advances in Therapy</i> , 2010 , 27, 828-36	4.1	28
100	The role of aripiprazole in Canada: A review of clinical and drug discontinuation data. Foreword. <i>Clinical Therapeutics</i> , 2010 , 32 Suppl 1, S1-2	3.5	1
99	Aripiprazole for the maintenance treatment of bipolar I disorder: A review. <i>Clinical Therapeutics</i> , 2010 , 32 Suppl 1, S32-8	3.5	21
98	Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. <i>Journal of Affective Disorders</i> , 2010 , 122, 27-38	6.6	125
97	Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. <i>Journal of Affective Disorders</i> , 2010 , 126, 358-65	6.6	82
96	Bipolar disorder and metabolic syndrome: an international perspective. <i>Journal of Affective Disorders</i> , 2010 , 126, 366-87	6.6	153

95	The relationship between testosterone and sexual function in depressed and healthy men. <i>Journal of Sexual Medicine</i> , 2010 , 7, 816-25	1.1	31
94	A cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 1518-25	4.6	83
93	When should you move beyond first-line therapy for depression?. <i>Journal of Clinical Psychiatry</i> , 2010 , 71 Suppl 1, 16-20	4.6	13
92	Attention-deficit/hyperactivity disorder in adults with bipolar disorder or major depressive disorder: results from the international mood disorders collaborative project. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2010 , 12,		38
91	Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 3061-75	4	26
90	Review: non-pharmacological interventions reduce antipsychotic induced weight gain. <i>Evidence-Based Mental Health</i> , 2009 , 12, 52	11.1	1
89	Cardiovascular and neurological adverse events associated with antidepressant treatment in children and adolescents. <i>Journal of Child Neurology</i> , 2009 , 24, 297-304	2.5	8
88	Relation between cigarette smoking and cognitive function in euthymic individuals with bipolar disorder. <i>Pharmacology Biochemistry and Behavior</i> , 2009 , 92, 12-6	3.9	15
87	Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. <i>Journal of Affective Disorders</i> , 2009 , 117 Suppl 1, S26-43	6.6	298
86	Exercise and bipolar disorder: a review of neurobiological mediators. <i>NeuroMolecular Medicine</i> , 2009 , 11, 328-36	4.6	38
85	Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. <i>Current Diabetes Reports</i> , 2009 , 9, 51-9	5.6	99
84	Teratogenesis associated with antibipolar agents. <i>Advances in Therapy</i> , 2009 , 26, 281-94	4.1	39
83	Psychotropic drugs and renal failure: translating the evidence for clinical practice. <i>Advances in Therapy</i> , 2009 , 26, 404-24	4.1	17
82	Long-acting risperidone: a review of its role in the treatment of bipolar disorder. <i>Advances in Therapy</i> , 2009 , 26, 588-99	4.1	12
81	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. <i>Bipolar Disorders</i> , 2009 , 11, 225-55	3.8	465
80	A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. <i>Bipolar Disorders</i> , 2009 , 11, 673-86	3.8	148
79	Asenapine versus olanzapine in acute mania: a double-blind extension study. <i>Bipolar Disorders</i> , 2009 , 11, 815-26	3.8	92
78	Health-care costs of pediatric clients developing adverse events during treatment with antipsychotics. <i>Value in Health</i> , 2009 , 12, 716-22	3.3	4

77	Discontinued psychiatric drugs in 2008. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1431-43	5.9	17
76	The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression?. <i>NeuroToxicology</i> , 2009 , 30, 497-521	4.4	75
75	Bipolar disorder and ADHD: Clinical concerns. <i>CNS Spectrums</i> , 2009 , 14, 8-9; discussion 13-4	1.8	9
74	Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, 240-6	4.6	45
73	Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, 1078-90	4.6	375
72	Introduction: Balancing the equation: managing comorbidities in patients with severe mental illness. <i>Journal of Clinical Psychiatry</i> , 2009 , 70 Suppl 3, 4	4.6	3
71	Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey. <i>Journal of Clinical Psychiatry</i> , 2009 , 70 Suppl 3, 5-11	4.6	39
70	Correlates of metabolic abnormalities in bipolar I disorder at initiation of acute phase treatment. <i>Psychiatry Investigation</i> , 2009 , 6, 78-84	3.1	19
69	Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. <i>Bipolar Disorders</i> , 2008 , 10, 1-37	3.8	222
68	Insulin, insulin-like growth factors and incretins: neural homeostatic regulators and treatment opportunities. <i>CNS Drugs</i> , 2008 , 22, 443-53	6.7	16
67	The relationship between childhood abuse and suicidality in adult bipolar disorder. <i>Violence and Victims</i> , 2008 , 23, 361-72	1.1	47
66	The hepatic safety profile of duloxetine: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008 , 4, 281-5	5.5	36
65	Validity of conclusions about quetiapine. <i>American Journal of Health-System Pharmacy</i> , 2008 , 65, 114-5; author reply 115-6	2.2	
64	Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. <i>JAMA Pediatrics</i> , 2008 , 162, 929-35		130
63	Recently patented agents with possible antipsychotic indication. <i>Expert Opinion on Therapeutic Patents</i> , 2008 , 18, 1327-1332	6.8	
62	Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders?. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 827-43	5.9	15
61	Assessing the prevalence of depression among individuals with diabetes in a Medicaid managed-care program. <i>International Journal of Psychiatry in Medicine</i> , 2008 , 38, 13-29	1	24
60	Considering wellness in managing patients with bipolar disorder. <i>CNS Spectrums</i> , 2008 , 13, 7-8	1.8	1

59	Conclusion: Summary and Recommendations. <i>CNS Spectrums</i> , 2008 , 13, 13-14	1.8	5
58	Adverse events in children and adolescents treated with antipsychotic medications. <i>Human Psychopharmacology</i> , 2008 , 23, 283-90	2.3	57
57	Acute treatment of patients with bipolar mixed episodes. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, e10	4.6	2
56	The effect of bipolar I disorder and major depressive disorder on workforce function. <i>Chronic Diseases in Canada</i> , 2008 , 28, 84-91		6
55	Aripiprazole: pharmacology and evidence in bipolar disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 1001-9	4	25
54	Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications. <i>Human Psychopharmacology</i> , 2007 , 22, 361-4	2.3	8
53	Measuring depressive symptoms in the naturalistic primary-care setting. <i>International Journal of Clinical Practice</i> , 2007 , 61, 1278-82	2.9	2
52	Problem gambling in bipolar disorder: results from the Canadian Community Health Survey. <i>Journal of Affective Disorders</i> , 2007 , 102, 27-34	6.6	40
51	Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms. <i>Journal of Affective Disorders</i> , 2007 , 100 Suppl 1, S5-14	6.6	22
50	Relationship between regional brain metabolism, illness severity and age in depressed subjects. <i>Psychiatry Research - Neuroimaging</i> , 2007 , 155, 203-10	2.9	39
49	Predictors of symptomatic remission in people with schizophrenia identified. <i>Evidence-Based Mental Health</i> , 2007 , 10, 73	11.1	
48	A preclinical and clinical rationale for quetiapine in mood syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 1211-9	4	46
47	Sex differences in antidepressant response in a Canadian primary-care sample. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 95-8	1.7	3
46	Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. <i>Current Opinion in Psychiatry</i> , 2007 , 20, 406-16	4.9	95
45	Thiazolidinediones: from antioxidant to neurotherapeutic?. <i>Medical Hypotheses</i> , 2007 , 69, 773-7	3.8	4
44	Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 1615-28	4	27
43	Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?. <i>Annals of Clinical Psychiatry</i> , 2007 , 19, 257-64	1.4	180
42	Predictors of self-reported antidepressant adherence. <i>Behavioral Medicine</i> , 2007 , 32, 127-34	4.4	62

41	Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 1352-7	4.6	54
40	Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 1480-91	4.6	189
39	Calculated bioavailable testosterone levels and depression in middle-aged men. <i>Psychoneuroendocrinology</i> , 2006 , 31, 1029-35	5	85
38	Association of the putative susceptibility gene, transient receptor potential protein melastatin type 2, with bipolar disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2006 , 141B, 36-43	3.5	71
37	One size fits all?. <i>Cmaj</i> , 2006 , 174, 1133-1134	3.5	1
36	Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. <i>Psychiatric Services</i> , 2006 , 57, 1140-4	3.3	148
35	The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. <i>Expert Opinion on Drug Safety</i> , 2006 , 5, 157-68	4.1	159
34	The effect of antidepressants on lipid homeostasis: a cardiac safety concern?. <i>Expert Opinion on Drug Safety</i> , 2006 , 5, 523-37	4.1	52
33	Measurable outcomes in psychiatric disorders: remission as a marker of wellness. <i>Clinical Therapeutics</i> , 2006 , 28, 1882-91	3.5	36
32	Improving outcomes in depression: a focus on somatic symptoms. <i>Journal of Psychosomatic Research</i> , 2006 , 60, 279-82	4.1	41
31	Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. <i>Canadian Journal of Psychiatry</i> , 2006 , 51, 274-80	4.8	111
30	Anxiety disorders and bipolar disorder: a review. <i>Bipolar Disorders</i> , 2006 , 8, 665-76	3.8	71
29	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. <i>Bipolar Disorders</i> , 2006 , 8, 721-39	3.8	168
28	The prevalence and impact of migraine headache in bipolar disorder: results from the Canadian Community Health Survey. <i>Headache</i> , 2006 , 46, 973-82	4.2	92
27	Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. <i>European Neuropsychopharmacology</i> , 2005 , 15, 573-85	1.2	165
26	Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 707-13	4	8
25	Open-label adjunctive topiramate in the treatment of unstable bipolar disorder. <i>Canadian Journal of Psychiatry</i> , 2005 , 50, 415-22	4.8	27
24	Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring. <i>Canadian Journal of Psychiatry</i> , 2005 , 50, 555-62	4.8	25

23	Antidepressant augmentation with raloxifene. <i>Journal of Clinical Psychopharmacology</i> , 2005 , 25, 96-8	1.7	9
22	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. <i>Bipolar Disorders</i> , 2005 , 7 Suppl 3, 5-69	3.8	274
21	Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. <i>Annals of Clinical Psychiatry</i> , 2005 , 17, 83-93	1.4	160
20	Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. <i>Cmaj</i> , 2005 , 173, 1327-34	3.5	95
19	Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship. <i>Cmaj</i> , 2005 , 172, 57-9	3.5	38
18	Comorbidity in bipolar disorder: a framework for rational treatment selection. <i>Human Psychopharmacology</i> , 2004 , 19, 369-86	2.3	51
17	Bipolar disorder: a national health concern. <i>CNS Spectrums</i> , 2004 , 9, 6-15	1.8	32
16	Treating bipolar disorder. Evidence-based guidelines for family medicine. <i>Canadian Family Physician</i> , 2004 , 50, 388-94	0.9	8
15	The human cost of not achieving full remission in depression. <i>Canadian Journal of Psychiatry</i> , 2004 , 49, 10S-16S	4.8	49
14	The antidepressant effects of risperidone and olanzapine in bipolar disorder. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2004 , 11, e218-26	2	4
13	Antipsychotic-induced weight gain: bipolar disorder and leptin. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 323-7	1.7	37
12	Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2003 , 48, 689-94	4.8	44
11	Valproate, bipolar disorder and polycystic ovarian syndrome. <i>Bipolar Disorders</i> , 2003 , 5, 28-35	3.8	85
10	The role of atypical antipsychotics in bipolar depression and anxiety disorders. <i>Bipolar Disorders</i> , 2003 , 5 Suppl 2, 20-35	3.8	42
9	What to do if an initial antidepressant fails?. <i>Canadian Family Physician</i> , 2003 , 49, 449-57	0.9	12
8	Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. <i>Bipolar Disorders</i> , 2002 , 4, 207-13	3.8	123
7	Assessing full remission. <i>Journal of Psychiatry and Neuroscience</i> , 2002 , 27, 235-9	4.5	65
6	Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 181-6	4.6	96

5	Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. <i>Canadian Journal of Psychiatry</i> , 2001 , 46, 273-81	4.8	181
4	Lithium revisited. <i>Canadian Journal of Psychiatry</i> , 2001 , 46, 322-7	4.8	25
3	Mechanisms of antipsychotic-induced weight gain. <i>Journal of Clinical Psychiatry</i> , 2001 , 62 Suppl 23, 23-9	4.6	14
2	Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination?. <i>Journal of Clinical Psychiatry</i> , 1999 , 60, 613-6	4.6	23
1	Risperidone treatment of bipolar disorder. <i>Canadian Journal of Psychiatry</i> , 1997 , 42, 88-90	4.8	13